NUVB

Company Overview — What Does Nuvation Bio Inc. Do?

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York. Nuvation Bio Inc. (NUVB) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David T. Hung and employs approximately 60 people. With a market capitalization of $1.6B, NUVB is one of the notable companies in the Healthcare sector.

Nuvation Bio Inc. (NUVB) Stock Rating — Reduce (April 2026)

As of April 2026, Nuvation Bio Inc. receives a Reduce rating with a composite score of 34.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NUVB ranks #3,805 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nuvation Bio Inc. ranks #640 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NUVB Stock Price and 52-Week Range

Nuvation Bio Inc. (NUVB) currently trades at $4.58. The stock lost $0.05 (1.1%) in the most recent trading session. The 52-week high for NUVB is $9.75, which means the stock is currently trading -53.0% from its annual peak. The 52-week low is $1.54, putting the stock 197.3% above its annual trough. Recent trading volume was 3.6M shares, reflecting moderate market activity.

Is NUVB Overvalued or Undervalued? — Valuation Analysis

Nuvation Bio Inc. (NUVB) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.13x, versus the sector average of 2.75x. The price-to-sales ratio is 72.03x, compared to 1.66x for the average Healthcare stock.

At current multiples, Nuvation Bio Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nuvation Bio Inc. Profitability — ROE, Margins, and Quality Score

Nuvation Bio Inc. (NUVB) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -68.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -35.2% versus the sector average of -33.1%.

On a margin basis, Nuvation Bio Inc. reports gross margins of 11.2%, compared to 71.5% for the sector. The operating margin is -2568.9% (sector: -66.1%). Net profit margin stands at -2260.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 814.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NUVB Debt, Balance Sheet, and Financial Health

Nuvation Bio Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $47M. Cash and equivalents stand at $99M.

NUVB has a beta of 1.44, meaning it is more volatile than the broader market — a $10,000 investment in NUVB would be expected to move 43.7% more than the S&P 500 on any given day. The stability factor score for Nuvation Bio Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nuvation Bio Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nuvation Bio Inc. reported revenue of $22M and earnings per share (EPS) of $-0.60. Net income for the quarter was $-209M. Gross margin was 11.2%. Operating income came in at $-227M.

In FY 2025, Nuvation Bio Inc. reported revenue of $63M and earnings per share (EPS) of $-0.60. Net income for the quarter was $-205M. Revenue grew 699.0% year-over-year compared to FY 2024. Operating income came in at $-213M.

In Q3 2025, Nuvation Bio Inc. reported revenue of $13M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-56M. Gross margin was 74.5%. Revenue grew 1704.7% year-over-year compared to Q3 2024. Operating income came in at $-56M.

In Q2 2025, Nuvation Bio Inc. reported revenue of $5M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-59M. Gross margin was 46.7%. Revenue grew 236.8% year-over-year compared to Q2 2024. Operating income came in at $-64M.

Over the past 8 quarters, Nuvation Bio Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $22M. Investors analyzing NUVB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NUVB Dividend Yield and Income Analysis

Nuvation Bio Inc. (NUVB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NUVB Momentum and Technical Analysis Profile

Nuvation Bio Inc. (NUVB) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

NUVB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nuvation Bio Inc. (NUVB) ranks #640 out of 838 stocks based on the Blank Capital composite score. This places NUVB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NUVB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NUVB vs S&P 500 (SPY) comparison to assess how Nuvation Bio Inc. stacks up against the broader market across all factor dimensions.

NUVB Next Earnings Date

No upcoming earnings date has been announced for Nuvation Bio Inc. (NUVB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NUVB? — Investment Thesis Summary

The quantitative profile for Nuvation Bio Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers. High volatility (stability score 26/100) increases portfolio risk.

In summary, Nuvation Bio Inc. (NUVB) earns a Reduce rating with a composite score of 34.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NUVB stock.

Related Resources for NUVB Investors

Explore more research and tools: NUVB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NUVB head-to-head with peers: NUVB vs AZN, NUVB vs SLGL, NUVB vs VMD.